The antibody drug, Zinplava, was first approved by the regulator in 2016 to prevent the recurrence of Clostridioides difficile infections (CDI).

CDI is generally caused by prolonged use of antibiotics, and can lead to potentially fatal diarrhea and inflammation of the colon.

The drugmaker did not immediately comment on the matter.

Zinplava will be discontinued on Jan. 31, the regulator s website showed, but no reason was cited for the decision.